Drug intelligence / Profile preview

SBE313

Development stage: Preclinical
Lead developer: Samsung Bioepis
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SBE313 is an antibody-drug conjugate (ADC) candidate currently in preclinical development by Samsung Bioepis in collaboration with Phrontline Biopharma. As a second-generation novel ADC candidate from Samsung Bioepis (following SBE303), SBE313 represents the company's expansion into innovative oncology therapeutics beyond their established biosimilar portfolio. The drug is in nonclinical development stages as of April 2026, with no publicly available information yet on its specific biological target, active ingredient composition, brand name, or specific cancer indications it will treat.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on SBE313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBE313.

Explore the full profile